on The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group Announces Shareholdings in Avadel Pharmaceuticals
The Vanguard Group, Inc. has disclosed its interests in Avadel Pharmaceuticals plc, a company involved in a takeover bid. As per the Form 8.3 filing under the Irish Takeover Panel rules, Vanguard holds 5,563,133 ordinary shares, representing a 5.71% stake in Avadel Pharmaceuticals as of November 18, 2025. The disclosure also outlined recent transactions, with Vanguard purchasing additional shares at prices of 22.94 USD and 23.08 USD per share.
No cash-settled or stock-settled derivatives were declared. Additionally, Vanguard reported no indemnity, option agreements, or other relevant securities agreements connected to the dealings in Avadel. This positions Vanguard as a notable shareholder in Avadel, participating actively in the current takeover proceedings.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all The Vanguard Group, Inc. news